ArticleBMC psychiatry2025
Examining valproate's potential anticancer effect among patients with bipolar disorder: a territory-wide active-comparator new user study spanning two decades.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsPreclinical studies have suggested potential anticancer effects of valproate, but clinical evidence is limited and inconclusive. This study aims to reexamine the relationship between valproate use and cancer incidence, using lithium as an active comparator in a cohort of patients with bipolar disorder.
methodsA retrospective, active-comparator, new-user cohort study was conducted using a territory-wide public healthcare database in Hong Kong. Patients diagnosed with bipolar disorder between 2003 and 2023 and initiating monotherapy of either lithium or valproate were included. Those with prior cancer diagnoses or concurrent use of other mood stabilizers were excluded. Cancer incidence was the primary outcome, analyzed using inverse probability of treatment weighting (IPTW) and modified Poisson regression.
resultsThe study included 5,875 valproate users and 1,439 lithium users. After a median follow-up of 2.96 years, 126 cases of cancer were observed (16 in lithium users and 110 in valproate users). There was no significant difference between valproate and lithium use among patients with bipolar disorder, with an adjusted incidence rate ratio (aIRR) of 1.13 (95% CI 0.66–1.91) for valproate compared to lithium. Results were consistent across subgroup and sensitivity analysis.
conclusionsOur findings do not suggest an anticancer effect from valproate but highlight the importance of weighing the other distinct safety and tolerability profiles of valproate and lithium against individual clinical presentations to ensure optimal and individualized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.